EACSGE
27.1.2020 18:26:12 CET | Business Wire | Press release
From February 13th to 14th , the Royal Hotel Carlton in Bologna will be venue of the first edition of the international congress organized by the EACSGE (Esophageal Adenocarcinoma Study Group Europe ), dedicated to basic and clinical research, diagnosis and therapy of gastroesophageal junction adenocarcinoma and Barrett's esophagus (a pathology secondary to gastroesophageal reflux disease, which can lead to esophageal adenocarcinoma).
The initiative is promoted by the EACSGE and coordinated by Sandro Mattioli , Professor at Alma Mater Studiorum - University of Bologna, Director of Thoracic Surgery and the Esophageal Diseases Center at Maria Cecilia Hospital (GVM Care & Research) in Cotignola (Ravenna, Italy) and Prof. Sheila K. Krishnadath of the University Medical Center in Amsterdam (Netherlands).
"For the first time, in the scientific world, basic researchers and clinical specialists in Medical Genetics, Anatomic Pathology, Gastroenterology, Surgery and Oncology will discuss and transform the results obtained in basic research into clinical applications, – Prof. Mattioli explains – in order to make advances in the treatment of esophageal adenocarcinoma , which is now the sixth most frequent cancer in the Western world".
The EACSGE boasts multidisciplinary teams from the Universities of Genoa, Helsinki and Verona, the Vita-Salute University and the European Institute of Oncology in Milan, and the Oncology Institute Research Hospital in Meldola (FC).
The main objectives of the meeting include taking stock of the current state of knowledge on the biology of the disease, determining the predictors of field cancerization in Barrett's esophagus, in order to implement targeted surveillance protocols and evaluating the efficacy of vaccines that show promise in being able to halt the field cancerization process.
The discussion among experts may provide knowledge that can be used to modulate surgical and pharmacological therapies at every stage of the disease. Finally, during the conference, meetings will be held among members of the EACSGE and the event’s Faculty, aimed at expanding the study groups and preparing new research protocols.
There is also space devoted to the future of research: young researchers will have the opportunity to deliver a short presentation on the scientific progress of their studies; the most accurate report will also receive an accolade from the Scientific Committee and the organizers.
The complete event schedule is available at this link: https://www.iec-srl.it/index.php/it/eventi-2020/201-traslational-reserach-for-tha-management-of-barrett-s-esophagus-and-esophageal-adenocarcinoma
View source version on businesswire.com: https://www.businesswire.com/news/home/20200127005551/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody18.6.2026 01:01:00 CEST | Press release
The companies have entered into a multi-year research collaboration, option and licensing agreement in which LabGenius Therapeutics will leverage its AI/ML-driven antibody discovery platform,EVA™, to design and engineer next-generation multispecifics with enhanced therapeutic properties LabGenius Therapeutics will receive an undisclosed upfront payment and potential early milestones, plus, if the option is exercised, potential triple-digit million clinical, regulatory, and commercial milestones, along with royalties on net sales LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together,
Joe Vernachio Named President of SOREL18.6.2026 00:00:00 CEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Joe Vernachio will be the next President of SOREL. Founded in 1962, SOREL is a leader in functional and lifestyle footwear that can be worn anywhere from the tundra to the streets of New York City. “We’re excited to welcome Joe Vernachio back to the Columbia Sportswear family,” said Tim Boyle, CEO and Chair of the Board. “Joe is a terrific leader who can build on the great work, talent and momentum in place at SOREL.” Mr. Vernachio led the Mountain Hardwear brand for several years, until he left to become the COO and ultimately, the CEO of Allbirds. His background also includes time as Global Vice President for Product and Operations at The North Face, and key roles at Nike, Spyder, Roots, Calvin Klein and Patagonia. “Joe is a consumer‑focused, collaborative leader with a deep passion for product and brand storytelling. His energy, experti
Venture Global and EnBW Announce New LNG Purchase Agreements17.6.2026 22:30:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and EnBW announced the execution of new, binding agreements for the purchase of approximately 0.82 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for approximately five years commencing in 2026, to be supplied from Venture Global’s portfolio. The new agreements add to the existing long-term sales and purchase agreements (SPAs) between Venture Global and EnBW for 2 MTPA for 20 years. “As one of Germany’s top LNG suppliers, Venture Global is proud to strengthen our partnership with EnBW and support the region’s energy security with a reliable supply of LNG,” said Venture Global CEO Mike Sabel. “The new mid-term agreements build on our strong, long-standing relationship with EnBW and reflects our commitment to meeting our customers’ evolving energy needs. Our dynamic marketing platform uniquely positions us to provide supply solutions across the short, medium, and long term.” About Venture Global Venture Globa
Kinaxis Announces Results of Voting at Annual and Special Meeting of Shareholders17.6.2026 22:05:00 CEST | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, received approval for all resolutions put forward to shareholders at today’s Annual and Special Meeting of Shareholders (the “Meeting”), as detailed in the Company’s management information circular dated May 5, 2026 (the “Circular”). 1. Election of Directors Shareholders voted to elect all eight directors nominated to the Kinaxis board, to hold office until the close of the next annual meeting of shareholders of the Company or until their successors are elected or appointed. Name of Nominee Total Number of Votes For Percentage of Votes For Total Number of Votes Against Percentage of Votes Against Razat Gaurav 21,870,163 99.01% 219,468 0.99% Robert Courteau 20,882,945 94.54% 1,206,685 5.46% Gillian (Jill) Denham 21,474,486 97.22% 615,143 2.78% José Alberto Duarte 21,699,181 98.23% 390,448 1.77% Lynn Loewen 21,952,244 99.38% 137,387 0.62% Angel Mendez 21,410,402 96
SES Announces Results of the Extraordinary General Meeting of Shareholders17.6.2026 19:23:00 CEST | Press release
SES (the “Company”) held an Extraordinary General Meeting (“EGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions. In particular, shareholders approved the cancellation of shares repurchased under the Company’s share buyback program of 2 November 2023, as amended on 2 May 2024, resulting in a corresponding reduction of the Company’s share capital. Shareholders also approved amendments to the Company’s articles of association, including indemnification for Board members and executives, as well as updates relating to the conduct of shareholder meetings. Detailed results on all matters voted on at the EGM will be available on the company’s webpage: https://www.ses.com/company/investors/shareholder-information/general-meeting-shareholders Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom